Low Dose Bolus Ketamine For Use In Sickle Cell Pain Crisis
Evaluation of a Standardized Low-Dose Bolus Ketamine Pathway for Management of Pediatric Sickle Cell Patients Presenting to the Emergency Department With Pain
Who can join
As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.
- Age
- 2 Years to 21 Years
- Sex
- All sexes
- Healthy volunteers
- Not accepted
- Compensation
- Not stated
Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.
What to expect
No one can promise a trial will help you personally — that is what the research is trying to find out.
What participation involves
Not stated in the study description — ask the study team about visits and procedures.
- Compensation
- Not stated
- Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
- Participants are monitored closely by the research team throughout the study.
- Some participants may receive access to an investigational treatment, which is still being studied.
- Your participation helps researchers learn whether this approach could help future patients.
About this study
In plain language
This study compares a low dose of ketamine with opioid pain medicines, such as morphine or Dilaudid, for sickle cell pain crises. It is for people with sickle cell disease who come to the Children's ER with a pain crisis. Researchers want to see if ketamine relieves pain faster and lowers the need for a hospital stay.
The goal of this study is to learn if Ketamine works more efficiently, as compared to Opioids, for Sickle Cell Pain The main questions it aims to answer are: Does Ketamine lower the number of times participants need to be admitted for continued pain control during a Sickle Cell Pain Crisis. Does Ketamine decrease the amount of time it takes to reach adequate pain control/pain score improvement, as compared to Opioids. Patients could have too low or too high blood pressure or sleepiness. Researchers will compare Ketamine to Opioids (Morphine or Dilaudid) to see if Ketamine works to treat pain enough that you do not need to be admitted to the hospital. Participants will: On arrival to the Children's ER for Sickle Cell Pain crisis will get Ketamine, instead of Morphine or Dilaudid, along with the typical Tylenol, Toradol, Lidocaine patch for pain control while in the ER. During this time we will follow your reported pain scale (0-10) to monitor your pain response to the Ketamine, as well as follow rate of hospital admission.
Compensation is read from the study's own description and may be missing — always confirm with the study team.
Eligibility
Who can join
- Have confirmed sickle cell disease of any type.
- Come to the ER with a sickle cell pain crisis caused by blocked blood flow.
- Give consent to join the study.
Who can't join
- Are allergic to ketamine.
- Have severe agitation or psychosis, which means losing touch with reality.
- Are pregnant.
- Have unstable blood pressure or blood flow, as judged by a doctor.
- Have high pressure inside the skull.
- Have severe liver problems.
- Have used ketamine in the past 24 hours.
- Come in for a problem other than a sickle cell pain crisis, such as fever, acute chest syndrome (a serious lung problem), stroke, or injury.
Simplified for readability. The official criteria below are what the study team uses.
Official eligibility criteria
Inclusion Criteria: * Confirmed Sickle Cell Disease (any genotype), Presenting to the Emergency Department with Vaso-occlusive crisis/pain crisis, Consent obtained Exclusion Criteria: * Ketamine allergy, Severe agitation/psychosis, Pregnancy, Hemodynamic instability (as judged by physician), Increased intracranial pressure, Severe hepatic impairment, Ketamine use within the previous 24 hours, Presentation for non-VOC-related pain (i.e. fever, acute chest syndrome, stroke, traumatic injuries etc).
Study sites (1)
MS
- University of Mississippi Medical Center, Pediatric Emergency Department · Jackson, MS 39216Cynthia Karlson, Ph.D. · Study contact · 601-984-2723 · ckarlson@umc.eduElizabeth Adeyemi, MD · Sub-investigatorLaci M Edwards, MD · Sub-investigatorMore trials in Jackson